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Background 8-Isoprostane is an accurate biomarker of oxidative stress. Despite 8-isoprostane concentrations in exhaled breath condensate (EBC) had showed higher values in chronic obstructive pulmonary disease (COPD), the association between EBC 8isoprostane and different clinical and functional parameters of COPD remains debatable. For this reason, the aim of this study was to evaluate the relation between EBC 8-isoprostane and the clinical and functional parameters of COPD. Participants and methods A cohort had been conducted including 100 participants classified into two groups matched for age and sex. Group A (COPD group) included 80 COPDs with different Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages; group B included 20 healthy controls. All COPD patients were assessed by high-resolution computed tomography of chest. Both groups had undergone spirometry, 6-min walk test, and SpO 2 assessment. EBC collection and 8-isoprostane had been measured for all participants in the study.
Results
Moderate and severe stages constituted the majority of recruited COPD patients. 8-Isoprostane concentration was significantly higher in COPD patients compared with controls. Forced expiratory volume in first second (FEV 1 ), 6-min walk test, and SpO 2 showed inverse significant correlation with 8-isoprostane. 8-Isoprostane also had higher levels in COPD patients with very severe GOLD stage. Smoking and sex were not predictive factors of higher 8-isoprostane. Conclusion 8-Isoprostane is considered a sensitive and valuable biomarker measured in EBC, reflecting the intensity of the inflammatory process in COPD. 8-Isoprostane showed a significant positive correlation with COPD GOLD stage and negative correlation with lung function.
Introduction
Chronic obstructive pulmonary disease (COPD) is a systemic inflammatory disease which affects mainly the lungs, caused by long-term exposure to indoor and outdoor pollution, most probably cigarette smoke. Airway obstruction which is considered the key factor in the pathophysiology of COPD is caused by cellular and structural modifications to the central and peripheral airways.
Additionally, the inflammatory cascade extends not only to the lung parenchyma, but also reaches peripheral tissues and pulmonary arteries. Despite COPD being a disease that involves mainly both lungs, it also leads to chronic systemic inflammation, and therefore could result in major extrapulmonary complications such as weight loss, skeletal muscle dysfunction, malignancy, osteoporosis, infections, and cardiovascular diseases [1] .
Airways in patients with COPD are exposed to increased oxidative stress and leukocyte infiltration [2] . One of the theories in the pathogenesis of COPD is the existence of imbalance between oxidants and antioxidants in the airway. 8-Epi-prostaglandinF 2α (8-isoprostane) is considered the most reliable marker to assess oxidative stress in vivo [3] . Isoprostanes are produced by free radicalcatalyzed lipid peroxidation of arachidonic acid and cell membrane phospholipids. Isoprostanes could reach the blood, secretions, and urine where the levels have been to be stable and reproducible in many experimental approaches [4] .
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Isoprostanes also entail strong biological actions so that they could strongly cause the progression of oxidantmediated lung diseases, such as COPD. Multiple researches had demonstrated increased 8-isoprostane in the exhaled breath condensate (EBC) of COPD patients [5] . There are, however, a number of doubtful issues with respect to the reliability and standardization of EBC [6] .
Induction of sputum is a standardized technique which successfully reveals local airway inflammation. Measuring 8-isoprostane in EBC was noticed to be elevated in both stable COPD [7] and exacerbations [8] ; however, the relationships of this biomarker and parameters that conclude predictive values in COPD remain largely underinvestigated [6] .
The present study aimed to measure 8-isoprostane levels in EBC of COPD patients and to evaluate the relation between EBC 8-isoprostane and the clinical and functional parameters of COPD.
Participants and methods
A cohort study including 100 participants (80 COPD patients − 20 healthy controls) was held between December 2016 and September 2017 in the Chest Department of Ain Shams University Hospitals, Egypt. A total of 80 patients diagnosed with COPD were recruited according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, 2016. The patients were classified into two groups: group A (COPD group) and group B (healthy controls).
Before beginning of the study, a detailed medical history focusing on respiratory symptoms was taken. Modified Medical Research Council scale for dyspnea was used according to standardized guidelines [9] . Patients with a history of bronchial asthma, allergic rhinitis, atopy, or other respiratory problems were excluded. All recruited COPD patients had no history of exacerbations, did not receive any antimicrobials or oral or inhaled corticosteroids in the past 4 weeks. After initial evaluation, all participants had undergone EBC 8-isoprostane measurement.
In addition, all COPD cases were examined radiologically by high-resolution computed tomography (HRCT) of the chest so as to detect the presence of emphysema. This research was accepted by the ethics committee and a written informed consent was obtained from all participants.
The 6-min walk test (6MWT) was performed to all participants [10] . The test was done along a straight corridor of 100-feet length. The distance of each lap is 30 m. Instructions were presented to all participants according to accepted recommendations [9] .
Spirometry
All COPD patients were evaluated by postbronchodilation spirometry after receiving 200 μg salbutamol through a metered-dose inhaler. Healthy controls also had undergone spirometry.
Exhaled breath condensate collection and 8isoprostane measurements
A specially designed condenser was used to collect EBC samples; it consisted of a glass chamber cooled by ice that was suspended in a larger glass chamber. Participants had been informed to breathe tidally through a mouthpiece connected to a condenser for 15 min without a noseclip. In order to decrease contaminated saliva, the two-way valve acted as a saliva trap, with a 12-cm banded tube situated perpendicular between the mouthpiece and the condenser while the mouth of the participant was kept at a lower position. Approximately 1-3 ml EBC was obtained and stored at −70°C in a 2-ml sterile plastic tube [11] . EBC 8-isoprostane level was measured using a specific enzyme immunoassay kit (Cayman Chemical, Ann Arbor, Michigan, USA).
Statistical analysis
Data were gathered and analyzed by the statistical package for the social sciences (IBM SPSS) version 20. Qualitative variables were expressed as number and percentages and quantitative variables were presented as mean, SD. Student's and Mann-Whitney tests were applied to compare between the two groups with quantitative parametric and nonparametric variables, respectively. Correlations between 8-isoprostane and quantitative variables were demonstrated by Pearson's correlation. Analysis of variance test was used to compare between more than two variables. P value of less than 0.05 was considered statistically significant.
Results
This cohort included 100 participants (80 COPD patients − 20 healthy controls). Both groups showed similarity regarding age and sex (P<0.05). Grades of severity among the COPD patients were revealed; 16 were considered mild, 24 moderate, 24 were severe, and 16 were very severe. Mean forced expiratory volume in first second (FEV 1 ) among COPD patients was significantly lower compared with controls (54.8 vs. 91.6%, respectively, P=0.000).
Smoking history was obtained from all participants which showed that 80% of the COPD patients were smokers compared with 45% of the healthy controls (P=0.003).
The majority of COPD patients were complaining of sputum production (75%). To assess dyspnea among all participants, the Modified Medical Research Council scale was recorded. The majority of COPD patients (55%) had dyspnea of grade 3.
COPD patients had undergone HRCT chest which showed 80% had emphysematous changes. Regarding SpO 2 and 6MWT, they were significantly lower in COPD patients when compared with controls (90.7 vs. 97.1%-313 vs. 433.6 m, respectively; P<0.05).
Significantly higher concentration of exhaled 8isoprostane was recorded in COPD patients in comparison to controls (24.9 vs. 6.3 pg/ml, respectively; P<0.05).
Significantly higher level of 8-isoprostane revealed in COPD patients had emphysematous changes (25.8 vs. 17.9; P=0.000).
Analysis of variance test had reported significantly higher concentrations of 8-isoprostane in patients
with very severe disease (P=0.000). The relationship between 8-isoprostane and either sex and smoking showed no significant correlation (P=0.932, 0.627, respectively); however, patients who complained of sputum production had significantly higher concentrations of 8-isoprostane than those who had not.
A significant positive correlation was demonstrated between 8-isoprstane and age, while it was negative with SpO 2 , 6MWT, and FEV 1 (r=0.233, −0.886, −0.983, −0,931).
Discussion
In the current study, it was shown that 8-isoprostane concentrations were higher in COPD cases in comparison to controls, along with the lung function decline. Negatively significant correlations were determined between 8-isoprostane and SpO 2 and 6MWT.
Although the fact that EBC 8-isoprostane did not show correlation with smoking history and sex, we reported a significant correlation between 8isoprostane concentration and the presence of emphysematous changes as measured by HRCT. According to the previous findings, and because 8isoprostane is a stable marker of oxidative stress, its level in EBC achieve clinical significance as a noninvasive biomarker of the underlying pathological cascade in COPD.
The significant correlation reported in the current study between 8-isprostane and presence of emphysematous changes reflects the strong association between oxidative stress and parenchymatous changes.
Regarding the relationship between 8-isoprostane and smoking, Inonu et al. [12] reported significant higher 8-isoprostane concentration in COPD patients and smokers compared with nonsmokers. Unbalanced oxidative stress leads to a direct impact on target cells of the airways through the production of oxidized mediators like isoprostanes, or indirect effect by stimulation of signal transduction pathways, transcription factors [13] , or via apoptosis [14] ( Tables 1-3 and Figs. 1 and 2) .
Regarding the previous data, the strong correlation between 8-isoprostane and emphysema reported in the current study may emphasize the undergoing inflammatory process in the lung parenchyma and it could give an explanation of COPD pathophysiology. In the present study, grades of disease severity and 8-isprostane were assessed. Its concentration was significantly increased in patients with very severe stage of the disease which could reflect also the association of 8-isoprstane and the clinical condition of the COPD patients; thus, it could be used as a marker of clinical improvement.
Additionally 8-isoprostane showed an inverse correlation with lung function reflected on the FEV 1 .
In contrast are the results reported previously by Makris et al. [15] , as in his study he did not find any relation between 8-isoprostane and lung function deterioration.
Several studies have confirmed absence of any association between 8-isoprostane and pulmonary function decline [12, 16, 17] . This contrast to our results could be referred to the oxidative burden (higher 8-isoprostane levels) on airways and lung parenchyma, which could be manifested by lung function impairment.
Sputum production is one of the most prevalent symptoms in COPD patients; EBC 8-isorostane was significantly higher in patients complained of sputum production.
In the present research, we had used the previous reported methods for collecting or analysis of breath condensate [17] . Increased concentrations of 8-isoprostane noticed in the current research with the usage of a competitive enzyme immunoassay is in agreement with multiple previous studies that have investigated this marker in the EBC of COPD patients [8, 16] . However, there are debatable issues regarding the advantage and standardization of 8-isorostane assessment in EBC as an oxidative stress marker [18] .
Conclusion 8-Isoprostane is considered a sensitive and valuable biomarker measured in EBC, reflecting the intensity of the inflammatory process in COPD. 8-Isoprostane showed a significant positive correlation with COPD GOLD stage and a negative correlation with lung function.
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Figure 1
Correlation between 8-isoprostane and 6-min walk test. 6MWT, 6-min walk test; EBC, exhaled breath condensate.
Figure 2
Correlation between 8-isoprostane and forced expiratory volume in first second. EBC, exhaled breath condensate; FEV 1 , forced expiratory volume in first second.
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